Salmonella subtypes with increased MICs for azithromycin in travelers returned to the Netherlands

Emerging Infectious Diseases

Volumn 20, Issue 4, 2014, Pages 705-708

  Hassing, Robert Jan ^a,b   Goessens, Wil H F ^a   van Pelt, Wilfrid ^c   Mevius, Dik J ^d,e   Stricker, Bruno H ^a,b   Molhoek, Nicky ^f   Verbon, Annelies ^a   van Genderen, Perry J J ^f,g  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Inspectorate of Health Care   (Netherlands)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

^e WAGENINGEN UNIVERSITY   (Netherlands)

^f Havenziekenhuis   (Netherlands)

^g Institute for Tropical Diseases   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; CHLORAMPHENICOL; CIPROFLOXACIN; TRIMETHOPRIM; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; CHILD; DISEASE TRANSMISSION; FEMALE; FEVER; HUMAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; NETHERLANDS; NONHUMAN; PREVENTION AND CONTROL; QUANTITATIVE ANALYSIS; SALMONELLA; SALMONELLOSIS; TRAVEL; ANTIBIOTIC RESISTANCE; DRUG EFFECTS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; PHYSIOLOGY; PROCEDURES; SALMONELLA INFECTIONS; TYPHOID FEVER;

ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CIPROFLOXACIN; DRUG RESISTANCE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; NETHERLANDS; SALMONELLA; SALMONELLA INFECTIONS; TRAVEL; TYPHOID FEVER;

EID: 84896441961     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2004.131536     Document Type: Article

References (15)

1. Parry CM. Typhoid fever. Curr Infect Dis Rep. 2004;6:27-33. http://dx.doi.org/10.1007/s11908-004-0021-6
2. Booker BM, Smith PF, Forrest A, Bullock J, Kelchlin P, Bhavnani SM, et al. Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother. 2005;49:1775-81. http://dx.doi.org/10.1128/AAC.49.5.1775-1781.2005
3. Leclercq R, Cantón R, Brown DF, Giske CG, Heisiq P, MacGowan AP, et al. EUCAST expert rules in antimicrobial susceptibility testing. Clin Microbiol Infect. 2013;19:141-60. http://dx.doi. org/10.1111/j.1469-0691.2011.03703.x
4. Gordillo ME, Singh KV, Murray BE. In vitro activity of azithromycin against bacterial enteric pathogens. Antimicrob Agents Chemother. 1993;37:1203-5. http://dx.doi.org/10.1128/AAC.37.5.1203
5. Metchock B. In-vitro activity of azithromycin compared with other macrolides and oral antibiotics against Salmonella typhi. J Antimicrob Chemother. 1990;25 Suppl A:29-31.
6. Butler T, Sridhar CB, Daga MK, Pathak K, Pandit RB, Khakhria R, et al. Treatment of typhoid fever with azithromycin versus chloramphenicol in a randomized multicentre trial in India. J Antimicrob Chemother. 1999;44:243-50. http://dx.doi.org/10.1093/jac/44.2.243
7. Parry CM, Ho VA, Phuong LT, Truong NT, Bay PVB, Lahn MN, et al. Randomized controlled comparison of ofloxacin, azithromycin, and an ofloxacin-azithromycin combination for treatment of multidrug-resistant and nalidixic acid-resistant typhoid fever. Antimicrob Agents Chemother. 2007;51:819-25. http://dx.doi. org/10.1128/AAC.00447-06
8. Girgis NI, Butler T, Frenck RW, Sultan Y, Brown FM, Tribble D, et al. Azithromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance. Antimicrob Agents Chemother. 1999;43:1441-4.
9. Chinh NT, Parry CM, Ly NT, Ha HD, Thong MX, Diep TS, et al. A randomized controlled comparison of azithromycin and ofloxacin for treatment of multidrug-resistant or nalidixic acid-resistant enteric fever. Antimicrob Agents Chemother. 2000;44:1855-9. http://dx.doi.org/10.1128/AAC.44.7.1855-1859.2000
10. Dolecek C, Tran TP, Nguyen NR, Le TP, Ha V, Phung QT, et al. A multi-center randomised controlled trial of gatifloxacin versus azithromycin for the treatment of uncomplicated typhoid fever in children and adults in Vietnam. PLoS ONE. 2008;3:e2188. http:// dx.doi.org/10.1371/journal.pone.0002188
11. Sjölund-Karlsson M, Joyce K, Blickenstaff K, Ball T, Haro J, Medalla FM, et al. Antimicrobial susceptibility to azithromycin among Salmonella enterica isolates from the United States. Antimicrob Agents Chemother. 2011;55:3985-9. http://dx.doi.org/10.1128/ AAC.00590-11
12. Capoor MR, Rawat D, Nair D, Hasan AS, Deb M, Aggarwal P, et al. In vitro activity of azithromycin, newer quinolones and cephalosporins in ciprofloxacin-resistant Salmonella causing enteric fever. J Med Microbiol. 2007;56:1490-4. http://dx.doi.org/10.1099/ jmm.0.47353-0
13. Rai S, Jain S, Prasad KN, Ghoshal U, Dhole TN. Rationale of azithromycin prescribing practices for enteric fever in India. Indian J Med Microbiol. 2012;30:30-3. http://dx.doi.org/10.4103/0255-0857.93017
14. Molloy A, Nair S, Cooke FJ, Wain J, Farrington M, Lehner PJ, et al. First report of Salmonella enterica serotype paratyphi A azithromycin resistance leading to treatment failure. J Clin Microbiol. 2010;48:4655-7. http://dx.doi.org/10.1128/JCM.00648-10
15. Hassing RJ, Goessens WH, Mevius DJ, van Pelt W, Mouton JW, Verbon A, et al. Decreased ciprofloxacin susceptibility in Salmonella Typhi and Paratyphi infections in ill-returned travellers: the impact on clinical outcome and future treatment options. Eur J Clin Microbiol Infect Dis. 2013;32:1295-301. http://dx.doi.org/10.1007/ s10096-013-1878-9